Dilsher Dhoot, MD, presents two cases involving DME and CRVO, that show remarkable anatomical improvement with a biosimilar comparable to those achieved with reference biologics.

Dilsher Dhoot, MD, provides an overview of biosimilars in retinal diseases and discusses how he identifies patients suitable for biosimilar therapy.

Patients considered vitamin D deficient had a risk of noninfectious uveitis more than twice that of their counterparts without vitamin D deficiency.

Investigators pointed out that spondyloarthritis (SpA) and Behçet’s disease are typical diseases that require the expertise of rheumatologists and ophthalmologists.

The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.

According to the company, its RELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe dry eye disease, and further explore the potential of a genetic biomarker. Topline results are expected in mid-2024.

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

The expert panel discusses what constitutes treatment failure in anti-VEGF therapy for nAMD and examines how various treatments may yield varying results in managing PED.

Adrienne Scott, MD, presents a case of neovascular AMD with PED in a patient who experiences a stroke while on anti-VEGF therapy.

Fish have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.

The company says top-line efficacy and safety data is on track for release in December of 2023.

According to the company, ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatment.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

Sunil Srivastava, MD, shares his experience using dexamethasone and fluocinolone acetonide implants to manage chronic non-infectious uveitis.

Sunil Srivastava, MD, details his approach to treating chronic non-infectious uveitis and macular edema, highlighting when to transition away from topical therapies.

Sunil Srivastava, MD, presents a case of postoperative macular edema, which required him to move beyond short-acting steroids to control the inflammation.